Today's News: Middle East
SEE OTHER BRANDS

Following the news from the Middle East

Today's News: Middle East: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today's News: Middle East.

Press releases published on August 30, 2025

Gideon Group CEO Salman Z. Khan Publishes LinkedIn Analysis on AI’s Impact on Mid-Level Roles

Gideon Group CEO Salman Z. Khan Publishes LinkedIn Analysis on AI’s Impact on Mid-Level Roles

Gideon Group CEO Salman Z. Khan shares a LinkedIn article examining AI’s effect on mid-level workforce roles and organizational structures. AZ, UNITED STATES, August 30, 2025 /⁨EINPresswire.com⁩/ -- Salman Z. Khan, CEO of The Gideon Group, has published a …

Dubai-Based MKV Luxury Introduces Zero-Deposit Option in Supercar Rentals

Dubai-Based MKV Luxury Introduces Zero-Deposit Option in Supercar Rentals

MKV Luxury: Redefining the Way Dubai Drives in Style DUBAI, DUBAI, UNITED ARAB EMIRATES, August 30, 2025 /⁨EINPresswire.com⁩/ -- In the city where luxury is a lifestyle, MKV Luxury Car Rental Dubai has quickly established itself as one of Dubai’s most …

KFSHRC Strengthens Its Position as a Fast-Growing Destination for International Patients

KFSHRC Strengthens Its Position as a Fast-Growing Destination for International Patients

RIYADH, Saudi Arabia, Aug. 30, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital …

Ceyone Launches 'Only Villas' — India’s First Digital Platform Exclusively for Villa Buyers

Ceyone Launches 'Only Villas' — India’s First Digital Platform Exclusively for Villa Buyers

Only Villas by Ceyone is India’s first digital platform dedicated to villa buyers, offering curated listings and a seamless buying experience. BANGALORE, KARNATAKA, INDIA, August 30, 2025 /⁨EINPresswire.com⁩/ -- First-time villa buyers, apartment …

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension

- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM - Acoramidis also demonstrated a significant 46% hazard …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions